News

Media

Conferences

Publications

Clinical

Events

Resources

Video

February 27, 2017

Medicare Part D and Oncology

Author(s):

Lauren Santye, Assistant Editor

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Related Videos

Lipoprotein particles | Image Credit: © komgritch - stock.adobe.com

Hands holding a crochet heart | Image Credit: © StockerThings - stock.adobe.com

Wooden blocks spelling HDL, LDL | Image Credit: © surasak - stock.adobe.com

Anticoagulant attacking blood clot | Image Credit: © BURIN93 - stock.adobe.com

Depiction of man aging | Image Credit: © Top AI images - stock.adobe.com

Map with pins | Image Credit: © Tryfonov - stock.adobe.com

Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com

Image Credit: © abricotine - stock.adobe.com

Senior Doctor is examining An Asian patient.

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.